Kala Pharmaceuticals (KALA) Misses Q4 EPS by 9c

Note: EPS may not be comparable

Kala Pharmaceuticals (NASDAQ: KALA) reported Q4 EPS of ($0.46), $0.09 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Can global equities keep rising? UBS sees these factors driving upside
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in